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Core evidence place in therapy summary for ciclesonide in persistent asthma

  **Outcome measure**                                                                           **Evidence**   **Implications**
  --------------------------------------------------------------------------------------------- -------------- -------------------------------------------------------------------------------------------------------------------
  **Patient-oriented evidence**                                                                                
  Improvement in asthma symptoms                                                                Clear          Effects are similar to other inhaled corticosteroids
  Reduction in rescue medication                                                                Clear          Effects are similar to other inhaled corticosteroids
  Improvement in quality of life                                                                Substantial    Beneficial effects on patient-perceived quality of life
  Reduction in oral corticosteroid use                                                          Moderate       Reduction in the regular use of oral corticosteroids likely to decrease the incidence of adverse systemic effects
  **Disease-oriented evidence**                                                                                
  Preservation of hypothalamic--pituitary--adrenal axis                                         Substantial    Lack of effect on hypothalamic--pituitary--adrenal axis for up to 1 year; suitable for use in pediatric patients
  Lower incidence of local adverse effects                                                      Clear          Fewer local adverse effects (e.g. oropharyngeal effects) compared with other inhaled corticosteroids
  Improvement in lung function (FEV~1~, FVC, PEF)                                               Clear          Ciclesonide as effective as budesonide and fluticasone, at least in the short term
  **Economic evidence**                                                                                        
  Cost effectiveness as an inhaled corticosteroid in persistent asthma in adults and children   No evidence    Evidence required

FEV~1~, forced expiratory volume in 1 s; FVC, forced vital capacity; PEF, peak expiratory flow.

Scope, aims, and objectives
===========================

Ciclesonide (Alvesco^®^, ALTANA Pharma AG), an airway-activated inhaled corticosteroid, has been developed for the management of persistent asthma. Its once-daily administration and airway activation may be advantageous in the treatment of asthma. Pharmacologically, the activation of ciclesonide to its active metabolite, desisobutyryl-ciclesonide (des-CIC), by airway esterases is novel. This local activation of drug provides concentrated activity of ciclesonide at the target organ, the lungs, and may decrease the potential for local and systemic adverse effects. Data from phase III clinical trials evaluating ciclesonide in the management of adult and pediatric patients with persistent asthma are available.

The purpose of this article is to review the place in therapy of ciclesonide in the management of patients with persistent asthma based on the available clinical evidence.

Methods
=======

The English language medical literature was reviewed for appropriate articles relating to ciclesonide for the treatment of asthma. The following databases were searched during August 2005 using the search terms "ciclesonide," "El 876," "By 90107," and "Alvesco": PubMed, <http://www.ncbi.nlm.nih.gov>EMBASE, <http://www.datastarweb.com>BIOSIS, <http://www.datastarweb.com>York University Centre for Reviews and Dissemination (CRD) databases, <http://www.york.ac.uk/inst/crd/crddatabases.htm>National Guideline Clearinghouse, <http://www.guideline.gov>Clinical trial registries, <http://www.clinicaltrials.gov>, <http://www.clinicalstudyresults.org>National Coordinating Centre for Health Technology Assessment (NCCHTA), <http://www.ncchta.org>Cochrane Database of Systematic Reviews (CDSR), <http://www.cochrane.org/index0.htm>National Institute for Health and Clinical Evidence (NICE), <http://www.nice.org.uk>Clinical Evidence (BMJ), <http://www.clinicalevidence.com>

No date limitations were placed on the search and only studies in patients with asthma were included. Abstracts from the American Thoracic Society (ATS) (<http://www.thoracic.org>) and the European Respiratory Society (ERS) meetings (<http://www.ersnet.org/ers>) for 2002--2005 were also reviewed using the same search terms to identify studies that have not yet been published in full.

Numerous guidelines related to asthma management were identified, but only two recent guidelines applicable on a global level were considered relevant for this review. No studies were identified from a review of clinical trials databases. A single Health Technology Assessment of ciclesonide was identified from the York University Centre.

The levels of evidence identified from the literature searches are summarized in [Table 1](#t1-ce-1-233){ref-type="table"}. Twenty full papers were identified in the initial search. Records were manually reviewed and 12 papers were excluded: pharmacokinetic (n=5), *in vitro* (n=1), animal studies (n=2), study other than a large, controlled clinical trial (n=3), or citations that mentioned ciclesonide but did not investigate its clinical use (n=1). Sixty-one abstracts were also reviewed manually. Exclusions included: published in full (n=4), pharmacokinetic (n=5), animal studies (n=6), *in vitro* (n=10), study other than a large, controlled clinical trial (n=11), and presentation of study results at more than one professional meeting (n=6).

The search was updated on February 7 and on June 30, 2006 and 22 new records were identified from the previous search. Eleven records were excluded as they were nonsystematic reviews (n=6), editorials (n=1), *in vitro* (n=2), small pharmacokinetic study (n=1), or an indication other than asthma (n=1). A systematic review ([@b26-ce-1-233]) was not included in the evidence base, as it was limited to small phase II studies comparing ciclesonide with other inhaled corticosteroids, rather than more recent larger phase III randomized controlled trials (RCTs).

In addition, a further level 3 pharmacokinetic study was identified and included ([@b51-ce-1-233]), along with 22 abstracts of meeting presentations, of which 4 were included following removal of duplicates.

Disease overview
================

Asthma, a chronic respiratory disease of both children and adults, is one of the most prevalent chronic diseases in the world affecting approximately 300 million people ([@b15-ce-1-233]; [@b46-ce-1-233]). An estimated 250 000 deaths caused by asthma occur annually; one in every 250 deaths worldwide is thought to be secondary to asthma ([@b15-ce-1-233]; [@b46-ce-1-233]).

The impact of asthma is far-reaching in both the adult and pediatric population and includes an effect on activities of daily living that extends to participation in school, work, and family life. Globally, about 15 million disability-adjusted life years (DALYs) are lost annually due to asthma, a number similar to that associated with diabetes, cirrhosis, or schizophrenia ([@b46-ce-1-233]). Direct medical costs related to medications and hospital admissions, and indirect medical costs related to loss of work and premature mortality are significant. Direct medical costs of asthma treatment account for up to 3% of total medical expenditures for many countries ([@b15-ce-1-233]).

Although the exact etiology of asthma remains poorly understood it is thought to have both genetic and environmental causes and is considered a chronic inflammatory disease. Asthma is characterized by bronchial hyperreactivity caused by chronic inflammation of the airways. Bronchial hyperreactivity is associated with reversible airflow obstruction and episodes of wheezing, breathlessness, chest tightness, and coughing (especially in the early morning or at night). There is no cure for asthma and the goal of treatment is to achieve and maintain control of symptoms, prevent exacerbations, reduce/eliminate side effects from medications, and allow patients to have an optimal quality of life. The potential for development of adverse effects associated with asthma treatment has been noted to impact patient adherence to therapy ([@b31-ce-1-233]).

Current therapy options
=======================

Over the past two decades the treatment of asthma has received increased attention and guidelines for the management of asthma have been published \[Global Initiative for Asthma (GINA) strategy, World Health Organization (WHO)/National Heart, Lung, and Blood Institute (NHLBI); [@b3-ce-1-233]). A global strategy for asthma management and prevention---the result of a collaborative effort of GINA, WHO, and the NHLBI---was first issued in 1995. Updates to this guideline have been released with the most recent being in 2004. Asthma management protocols and guidelines focus on the inflammatory component of the disease and recommend a stepped-care approach to disease management ([Table 2](#t2-ce-1-233){ref-type="table"}).

Many pharmacologic entities are available for the chronic management of persistent asthma, but inhaled corticosteroids are the cornerstone of therapy. Corticosteroids can be administered either orally or via inhalation, although the adverse effect profile significantly favors the latter. Inhaled corticosteroids are considered the most effective therapy for persistent asthma and are the preferred treatment for all patients with persistent disease symptoms ([@b3-ce-1-233]).

All of the available inhaled corticosteroids produce their effects by interacting with intracellular glucocorticoid receptors, which are present throughout the body. In the treatment of asthma, the effect of these agents on pulmonary glucocorticoid receptors produce the desired effects but interaction with glucocorticoid receptors outside the lungs can lead to unwanted adverse effects such as suppression of the hypothalamic--pituitary--adrenal axis (HPA), reduction of bone density, and growth suppression. Beneficial pharmacologic effects of these agents include decreasing inflammatory cells in the airway and increasing the release of antiinflammatory cytokines ([@b35-ce-1-233]). The decrease in inflammatory mediators results in a reduction of airway inflammation and hyperreactivity, improved pulmonary function, symptom control, and reduction of exacerbations ([@b40-ce-1-233]).

The principal goal of inhaled corticosteroid therapy is to have a high level of antiinflammatory effect with minimal adverse effects ([@b40-ce-1-233]). Although differences in pharmacokinetic parameters and potency exist, the currently available agents ([Table 3](#t3-ce-1-233){ref-type="table"}) are considered equally efficacious when administered at equipotent doses ([@b56-ce-1-233]). The ideal inhaled corticosteroid for patients with asthma has a high degree of lung deposition with a low level of systemic bioavailability providing therapeutic benefit (high glucocorticoid receptor affinity) without significant adverse effects. Systemic exposure can be minimized by high protein binding and a rapid clearance rate ([@b9-ce-1-233]). Use of a prodrug that is not pharmacologically active until it undergoes a metabolic transformation has been shown to decrease oropharyngeal effects and might result in improved pulmonary targeting ([@b35-ce-1-233]).

Smaller particle size, physical properties of the compounds, delivery device used, and inhaler technique all have an impact on the rate of lung deposition ([@b35-ce-1-233]). Higher rates of lung deposition translate to an increased amount of drug available at the intended site of action (lungs) and a lower amount available for oral absorption and systemic availability, and hence fewer adverse effects. In addition, lipid conjugation of the compound can provide a reservoir in the lungs allowing for a slow release of active compound ([@b9-ce-1-233]).

Of particular concern for long-term treatment of persistent asthma is an agent's propensity to cause systemic side effects. Systemic exposure to an inhaled corticosteroid is tied to its potential for adverse effects. There is little concern about systemic effects with the use of low-dose inhaled corticosteroids (doses of ≤500 mcg budesonide or equivalent) ([@b3-ce-1-233]). However, at high doses concern remains that these medications may cause HPA axis suppression, decreased bone mineralization, cataracts, glaucoma, and a reduction in the rate of bone growth in children. It is important to note that while HPA axis suppression and decreased osteoblast activity have been reported with high-dose inhaled corticosteroid therapy, the clinical significance of these effects is controversial. Additionally, patients receiving high doses of inhaled corticosteroids may be exposed to intermittent courses of systemic glucocorticoids that complicate the assessment of the impact of high-dose inhaled corticosteroid treatment alone ([@b3-ce-1-233]). Of the available inhaled corticosteroids, comparative studies have shown that budesonide, mometasone, and fluticasone have a lower potential to cause systemic effects as compared with beclomethasone dipropionate and triamcinolone ([@b22-ce-1-233]; [@b3-ce-1-233]).

Ideally, once a patient's symptoms are controlled, the dose of inhaled corticosteroid should be reduced to the minimum effective dose to promote safe and cost-effective asthma control ([@b16-ce-1-233]). Unfortunately, this approach is not always undertaken and patients are not infrequently exposed to unnecessarily high doses and an increased risk of adverse effects ([@b56-ce-1-233]).

Beyond the specific drug selected, the device used to deliver the therapeutic entity can have a profound effect on treatment outcome. In an attempt to maximize drug delivery to the lungs, a variety of inhaler devices have been developed. The device also impacts the efficacy of therapy and has associated advantages and disadvantages ([Table 4](#t4-ce-1-233){ref-type="table"}). The delivery device as well as the specific drug evaluated and the dose selected must all be considered when evidence of inhaled corticosteroid efficacy and adverse effects are taken into account. Environmental concerns have mandated alternatives to the use of chlorofluorocarbon (CFC) propellants in metered-dose inhalers. The change to hydrofluoroalkane propellants has resulted in some products that have different characteristics from previous formulations ([@b24-ce-1-233]). Therefore, interpretation of reported efficacy and adverse effect data also requires an understanding of the propellant used.

Even at low daily doses, local adverse effects (dysphonia, oral candidiasis, and pharyngitis) to inhaled corticosteroids are reported at widely varying rates (5--58%) ([@b66-ce-1-233]). The reported prevalence of these local effects is influenced by the type of study, length of observation, delivery device used, and method for recording (questionnaire or clinical examination). Local adverse effects may complicate treatment and lead to a disruption of therapy and worsening of disease.

Despite advances in delivery device and drug development, there is still a need for inhaled corticosteroid therapies that are highly specific to the site of action, the lungs, with minimal systemic absorption. Ciclesonide was developed in response to this need.

Clinical evidence with ciclesonide in asthma
============================================

Level 2 evidence from fully published studies investigating the efficacy and safety of ciclesonide is available, including placebo-controlled studies ([@b21-ce-1-233]; [@b41-ce-1-233]; [@b58-ce-1-233]; [@b7-ce-1-233]; [@b29-ce-1-233]) and trials with active comparator ([@b18-ce-1-233]; [@b55-ce-1-233]; [@b13-ce-1-233]; [@b34-ce-1-233]). Further evidence is also currently available in abstract form only, hindering full critical appraisal. Outcomes studied include disease-oriented measurable endpoints of respiratory function, inflammatory markers, and HPA suppression, as well as patient-oriented outcomes such as asthma symptoms, health-related quality of life (HRQOL), and use of rescue medication. Comparator drug propellant is not consistently reported which makes an assessment of delivery device difficult.

Ciclesonide is a prodrug whereas the other inhaled corticosteroids are delivered to the site of action in their active form. Ciclesonide is converted to its active and highly potent metabolite, des-CIC, by esterases in the airways, thus providing active drug at the intended site of action. Ciclesonide is also formulated in solution which in comparison with suspensions is likely to improve lung deposition characteristics ([@b9-ce-1-233]). In addition, other properties of ciclesonide and des-CIC, including low oral bioavailability (\<1%), rapid systemic clearance and a high degree of plasma protein binding (99%) are designed to reduce the potential for systemic side effects.

Therefore, the pharmacologic and pharmacokinetic characteristics of ciclesonide are intended to provide advancements in the treatment of asthma with a potentially improved safety profile.

Systemic absorption
-------------------

In human lung tissue, a reversible lipid conjugation of des-CIC has been demonstrated. This may account for the prolonged antiinflammatory activity of inhaled ciclesonide in the lungs as this conjugated des-CIC may act as a reservoir ([@b9-ce-1-233]).

The small particle size of ciclesonide improves its pulmonary deposition; studies have shown that up to 52% of an inhaled dose of ciclesonide is deposited in the small airways and alveoli following administration, and that the amount of deposition is not influenced by the use of a spacer device ([@b25-ce-1-233]; [@b54-ce-1-233]). The pharmacokinetics of ciclesonide and des-CIC are similar in healthy subjects and in patients with asthma, confirming that airway activation of the drug is unimpaired by the disease ([@b51-ce-1-233]).

Compared with fluticasone and budesonide, smaller amounts of ciclesonide are available for systemic absorption through the gastrointestinal tract as lower amounts are deposited in the mouth and oropharynx. In a study of adults with bronchial asthma, the oropharyngeal deposition of ciclesonide was about 50% of that reported with fluticasone propionate, with 90% less des-CIC present in the oropharyngeal cavity compared with fluticasone following inhalation ([@b64-ce-1-233]). Following administration of ciclesonide and budesonide to healthy volunteers, the maximal concentrations of ciclesonide and des-CIC recovered from oropharyngeal wash were 30% and 0.67% of budesonide, respectively ([@b49-ce-1-233]). Ciclesonide and budesonide concentrations in the wash decreased rapidly within 15 min of administration. The concentrations of des-CIC in the oropharynx 60 min after inhalation were only 4% of the budesonide concentration ([@b49-ce-1-233]), and 8% of the fluticasone concentration ([@b64-ce-1-233]).

Ciclesonide undergoes first-pass hepatic inactivation (\>99%) following oral administration, rendering systemic bioavailability from the oral route essentially negligible ([@b48-ce-1-233]). Furthermore, there is a low potential for adverse systemic side effects with inhaled ciclesonide as it is highly protein bound (\>99%) and a low fraction of unbound active metabolite is available in the systemic circulation ([@b65-ce-1-233]). The unbound fraction is also rapidly cleared further limiting systemic availability ([@b9-ce-1-233]).

Pulmonary function
------------------

Laboratory measures of forced expiratory volume in 1 s (FEV~1~), forced vital capacity (FVC), and peak expiratory flow (PEF) provide a direct, objective measure of treatment effect on airflow limitation in asthma. Use of a spirometer to assess FEV~1~ and FVC is helpful for diagnosing and monitoring the progress of asthma and response to therapy. Measurement of PEF with a peak expiratory flow meter can provide additional asthma monitoring information. However, PEF measures are not interchangeable with FEV~1~ and FVC, and do not always correlate with asthma severity; the relationship between FEV~1~ and PEF and asthma severity, airway inflammation, and HRQOL is complex and not well established.

Initial phase II studies documented a decrease in airway hyperresponsiveness after adenosine monophosphate (AMP) challenges with ciclesonide therapy; efficacy was similar to that of both fluticasone and budesonide ([@b72-ce-1-233]; [@b39-ce-1-233]; [@b43-ce-1-233]; [@b23-ce-1-233]).

In placebo-controlled trials, ciclesonide demonstrated improvements in pulmonary function over a range of doses in patients with asthma with varying degrees of severity from mild to severe ([Table 5](#t5-ce-1-233){ref-type="table"}). Single daily ciclesonide doses of at least 80 mcg daily were associated with significant improvements from baseline in pulmonary function compared with placebo ([@b41-ce-1-233]). Studies comparing single daily ciclesonide doses of 800 and 1600 mcg have not demonstrated superiority of the higher dose regimen ([@b20-ce-1-233]; [@b57-ce-1-233]). More recent data, however, show that compared with ciclesonide 160 mcg once daily, ciclesonide 320 mcg twice daily resulted in significantly improved PEF (*P*=0.0014) in 680 patients with severe asthma ([@b6-ce-1-233]). A dose--response effect was also demonstrated in a 3-week study investigating ciclesonide 40, 80, 160, and 320 mcg on exercise-induced bronchoconstriction in 26 patients with mild asthma ([@b70-ce-1-233]). Daily dosing given either in the morning or in the evening is associated with positive treatment response ([@b61-ce-1-233]).

Ciclesonide 80 mcg has also been shown to block allergen-induced lung function responses and measures of airway inflammation in patients with mild atopic asthma ([@b28-ce-1-233]). In this randomized three-way crossover study 21 patients were treated with ciclesonide 40 or 80 mcg or placebo for 7 days and challenged with inhaled allergen. Compared with placebo, ciclesonide 80 mcg/day attenuated the allergen-induced airway response (*P*\<0.025), the sustained fall in FEV~1~ measures 24 hours postchallenge (*P*\<0.025), and the allergen-induced accumulation of eosinophils into the airways (*P*\<0.025). Similarly, after 4 weeks of treatment with ciclesonide 160 mcg once daily, inflammatory response as assessed by AMP bronchial challenge, exhaled nitric oxide, and sputum eosinophil count was significantly reduced in 17 patients with asthma ([@b81-ce-1-233]).

In larger studies comparing ciclesonide treatment with an active control, significant improvements in airflow (changes in FEV~1~ and FVC) were reported with ciclesonide and active control in all studies---with the exception of [@b13-ce-1-233] ([Table 6](#t6-ce-1-233){ref-type="table"}). Neither treatment with budesonide nor ciclesonide resulted in improved FEV~1~ or FVC; however, the decrease in FVC was significantly less with ciclesonide than with budesonide (*P*=0.01). The decline in FEV~1~ seen with both drugs was expected, since all patients routinely required "moderate" doses of inhaled corticosteroids to control their asthma, were poorly controlled, and had received budesonide 1280 mcg/day during a 2- to 4-week run-in phase, which was stopped prior to randomization to the study regimens. A subsequent abstract by the same authors reported that treatment with ciclesonide 320 mcg once daily and fluticasone propionate 200 mcg twice daily improved FEV~1~ to a comparable degree (171 mL and 186 mL, respectively; *P*\<0.0001 vs baseline) ([@b14-ce-1-233]).

PEF values were also significantly improved from baseline with ciclesonide and active treatment ([Table 6](#t6-ce-1-233){ref-type="table"}). In one study comparing evening administration of ciclesonide 320 mcg and budesonide 400 mcg, onset of treatment effect as evidenced by daily recordings of morning PEF was observed on day 3 with ciclesonide compared with week 2 with budesonide ([@b12-ce-1-233]). Differences between ciclesonide and active control were not statistically significant. Similarly, maintenance of pulmonary function with ciclesonide 160 mcg (dosed either in the morning or evening) was not statistically different with budesonide 200 mcg twice daily ([@b55-ce-1-233]). However, an 8-week study reported in abstract form reported a significant difference (*P*=0.001) in PEF in favour of ciclesonide 320 mcg twice daily compared with budesonide 400 mcg twice daily ([@b1-ce-1-233]).

These results are predominantly obtained from studies of 12 weeks' duration. In a 40-week open-label extension of a 12-week double-blind study evaluating ciclesonide 800 mcg/day and 1600 mcg/day, the improvement in FEV~1~ was sustained throughout the study period ([@b57-ce-1-233]). Over a 52-week study period, FEV~1~ increased significantly over baseline in patients treated with ciclesonide 200 mcg/day (*P*=0.0072) and 800 mcg/day (*P*=0.0237) ([@b20-ce-1-233]).

Finally, ciclesonide 640 mcg twice daily was as effective as oral prednisolone 40 mg once daily in improving lung function in 130 patients with acute asthma exacerbation, without causing HPA suppression ([@b62-ce-1-233]).

Use of oral corticosteroids
---------------------------

Since the regular use of oral corticosteroids is associated with significant adverse systemic effects, the impact of inhaled corticosteroid therapy on daily oral corticosteroids required to control symptoms in patients with persistent asthma is an important measure of efficacy. Use of inhaled corticosteroids has been associated with a reduction in the use of oral corticosteroids ([@b42-ce-1-233]). In a 12-week trial of 141 patients with severe, persistent asthma, use of ciclesonide significantly reduced the need for oral corticosteroid at doses of 320 or 640 mcg twice daily compared with placebo. Mean percentage change in oral corticosteroid use from baseline was −47.39 (low-dose ciclesonide, *P*=0.0003 vs placebo), −62.54 (high-dose ciclesonide, *P*=0.0001 vs placebo), and +4.2 (placebo) ([@b7-ce-1-233]).

Asthma symptom score and use of rescue medications
--------------------------------------------------

Evidence from large controlled trials that have evaluated ciclesonide and either placebo or a comparator drug indicate that ciclesonide is at least as effective in reducing patient-reported asthma symptoms and use of rescue medications ([Table 7](#t7-ce-1-233){ref-type="table"}). For example, daily albuterol use as rescue medication was reduced significantly in all ciclesonide-treated groups (80, 160, and 320 mcg) but increased in the placebo group ([@b58-ce-1-233]). A dose--response effect has been demonstrated, with half as many patients receiving ciclesonide 320 mcg twice daily experiencing an asthma exacerbation compared with those taking ciclesonide 160 mcg/day (23 \[6.7%\] vs 43 \[12.7%\] patients) ([@b6-ce-1-233]). The higher dose was also associated with significantly lower use of rescue medication (*P*=0.0005) and improved symptom scores (*P*=0.0108) than the lower dose.

In one study comparing inhaled doses of ciclesonide 80 mcg once daily, ciclesonide 160 mcg once daily, and fluticasone propionate 88 mcg twice daily in patients with mild-to-moderate persistent asthma, the percentage of days without asthma symptoms and without the need for rescue medications (84--87% for mild disease; 70--79% for moderate disease) was similar for all treatment groups and was highest during the last 4 weeks of the 12-week study (Magnussen et al. 2005). This increase in the last 4 weeks of a 12-week trial was also observed by [@b19-ce-1-233]. The percentage of symptom-free days was higher in those patients treated with ciclesonide (91%) than in patients treated with fluticasone (83%, significance not reported), although the percentage of days not requiring rescue medication was comparable (89 vs 91%, respectively) ([@b19-ce-1-233]). A full publication of this study by the same authors reported comparable changes in asthma symptom scores for ciclesonide and fluticasone (reductions of 0.75 and 0.86, respectively) ([@b18-ce-1-233]). Ciclesonide 320 mcg once daily was comparable to fluticasone 200 mcg twice daily in percentage of days without symptoms (88% both groups) or use of rescue medication (85 and 84%, respectively) after 12 weeks in 472 patients with moderate asthma ([@b14-ce-1-233]). [@b8-ce-1-233]) adds to the evidence that ciclesonide is equivalent in efficacy to fluticasone.

Patients treated with ciclesonide 160 mcg (dosed either in the morning or in the evening) or budesonide 200 mcg twice daily experienced equivalent periods of symptom-free days (89, 91, and 93%, respectively) ([@b55-ce-1-233]). In addition, other outcomes including rescue medication use, days with control of asthma symptoms, and days without PEF fluctuation were maintained versus baseline with no significant differences between the three groups. In contrast, [@b1-ce-1-233] reported significantly lower use of rescue medication (*P*=0.007) and improved symptom scores (*P*=0.008) with ciclesonide 320 mcg twice daily compared with budesonide 400 mcg twice daily after 8 weeks' treatment in 319 patients with moderate to severe asthma. Similarly, although overall judged as having comparable efficacy, ciclesonide 320 mcg once daily resulted in significantly more symptom-free days compared with budesonide 320 mcg once daily in 359 patients with persistent asthma ([@b13-ce-1-233]).

Use in children
---------------

The efficacy of ciclesonide in children has been compared with placebo, budesonide, and fluticasone.

In a large double-blind, randomized trial involving 1031 children aged 4--11 years, mean FEV~1~ percent predicted increased by 11.97, 13.58, and 14.17, and mean absolute FEV~1~ increased by 250, 280, and 290 mL versus placebo after 12 weeks' treatment with ciclesonide 40, 80, and 160 mcg once daily, respectively ([@b29-ce-1-233]). Morning and evening PEF also increased, the latter by 12.27, 18.34, and 15.78 L/min. The changes seen with ciclesonide 80 and 160 mcg/day were significant versus placebo. These improvements were associated with significantly more symptom-free days among children receiving ciclesonide 80 (52.44%; *P*\<0.0001) and 160 mcg/day (48.77%; *P*=0.0139) compared with placebo (42.52%), and significantly lower use of rescue medication (*P*\<0.01). Ciclesonide improved symptom scores and reduced nighttime awakening at all three doses.

There is evidence that ciclesonide 160 mcg/day, given either as a single dose or as 80 mcg twice daily, is as effective as fluticasone 88 mcg twice daily and budesonide 400 mcg once daily. In 556 children, ciclesonide and fluticasone increased mean FEV~1~ by 298 and 297 mL, respectively, after 12 weeks ([@b59-ce-1-233]). Corresponding increases in mean morning and evening PEF were 31 and 29 L/min with ciclesonide, and 34 and 29 L/min with fluticasone.

Mean FEV~1~ increased by 220 mL in 340 children aged 6--11 years following 12 weeks' treatment with ciclesonide and by 253 mL in 173 receiving budesonide ([@b77-ce-1-233]). Asthma symptoms were absent in an almost identical proportion of days in each group (74% for ciclesonide and 73% for budesonide), and both drugs were comparable in improving symptom scores and reducing rescue medication use.

Quality of life
---------------

HRQOL measures offer an important patient perspective into the therapeutic management of asthma. Because asthma is a chronic disease that may affect a patient's ability to participate in normal daily activities including work, school, and extracurricular activities, it is important to include the impact of a medication on quality of life in a determination of its effectiveness and place in therapy. There is often a disconnection between medication-induced changes in airways as assessed by the clinician and patient perceptions of their functional status. The effect of treatment on HRQOL is now recognized as an important gauge of therapy and should be used as a determinant of treatment effect. HRQOL measurement provides the clinician with important insight into the burden of disease and provides an appreciation of the effect of treatment on functional status. Treatments with positive HRQOL effects may improve patient compliance with therapy and improve overall patient satisfaction ([@b30-ce-1-233]).

Although several HRQOL tools have been used to evaluate HRQOL in patients with asthma, in the ciclesonide studies that provided HRQOL information, the Asthma Quality of Life Questionnaire (AQLQ) and the Pediatric Asthma Quality of Life Questionnaire (PAQLQ) were the tools used for assessment. The reliability and validity of the AQLQ has been verified in several studies ([@b32-ce-1-233]; [@b74-ce-1-233]; [@b67-ce-1-233]). The AQLQ is a 32-item, four-domain (symptoms, emotional function, activity limitation, and breathlessness) questionnaire that can be interviewer- or self-administered. Using this questionnaire, a change in score of 0.5 is considered the minimum change necessary for clinical significance.

A separate pediatric-based questionnaire is necessary for children because it is clear that conventional measures of the effectiveness of therapy (asthma severity, spirometry, and medication use) and parents' perceptions of a child's functionality weakly correlate with how children actually feel and their ability to participate in activities of daily life ([@b38-ce-1-233]). The PAQLQ is a 23-item questionnaire that is appropriate for children between the ages of 7 and 17 years and focuses on three domains (symptoms, emotional function, and activity limitation). A change in score of 0.5 reflects a minimally important difference. Both interviewer- and self-administration formats of the PAQLQ are available ([@b37-ce-1-233]).

The impact of ciclesonide on the HRQOL of patients with asthma has been assessed ([Table 8](#t8-ce-1-233){ref-type="table"}) ([@b10-ce-1-233]; [@b47-ce-1-233]; [@b52-ce-1-233]). In one study that included patients with severe persistent asthma (FEV~1~ 40--65%), clinically significant changes in AQLQ (≥0.5) were noted in all three groups receiving ciclesonide 160 or 320 mcg, or fluticasone 440 mcg twice daily ([@b10-ce-1-233]). The change in AQLQ with fluticasone was greater than that noted with either dose of ciclesonide, although the statistical significance of this difference was not reported. These HRQOL studies were only conducted for a period of 12 weeks, therefore, it is not known if improvements in QOL are sustainable or whether the changes translate to significant long-term patient improvement.

Tolerability
------------

A major component of the rationale for the development of ciclesonide is the minimization of local and systemic side effects often experienced with inhaled corticosteroids. Ciclesonide has been well tolerated in clinical trials with most adverse effects reported as mild. It is anticipated that the airway activation of ciclesonide will reduce the incidence of adverse effects compared with currently available inhaled corticosteroids. Although there are some data from longer term studies, the bulk of the evidence supporting the lack of systemic effects with ciclesonide therapy is limited to 12 weeks of treatment. Further long-term data will be necessary to confirm if ciclesonide offers an advantage over the other inhaled corticosteroids.

### Local adverse effects

Local adverse effects associated with the use of inhaled corticosteroids include perioral dermatitis, tongue hypertrophy, cough during inhalation, and sensation of thirst. The most frequently reported clinically significant effects are oropharyngeal candidiasis and dysphonia ([@b66-ce-1-233]). Deposition of active medication in the oropharyngeal cavity is dependent on the delivery device and can be decreased with the use of spacers. These adverse effects, while they are not considered to be clinically serious, are troublesome and may affect patient adherence ([@b31-ce-1-233]).

Oropharyngeal deposition of ciclesonide (metered-dose inhaler with hydrofluoroalkane propellant) is reduced compared with fluticasone (metered-dose inhaler with hydrofluoroalkane propellant) and budesonide (metered-dose inhaler with CFC) ([@b49-ce-1-233]; [@b64-ce-1-233]). This reduction in oral deposition is expected to correlate with a lower rate of local adverse effects. In a pooled analysis of phase II and phase III studies, data from 12 251 patients who received ciclesonide (n=7706), active control \[budesonide, beclomethasone, or fluticasone (n=3330)\], or placebo (n=1215) for 12 weeks were analyzed to determine the incidence of oropharyngeal adverse events (candidiasis, hoarseness, cough) ([@b27-ce-1-233]). The incidence of local adverse events per patient year was similar in the ciclesonide and placebo group; oral candidiasis and hoarseness occurred less frequently in the ciclesonide group compared with the active control group (*P* value not reported) ([Table 9](#t9-ce-1-233){ref-type="table"}). In a subanalysis, fewer patients in the ciclesonide group experienced an oral adverse event compared with patients in the fluticasone subgroup (*P*\<0.0001).

There is limited evidence that this lower frequency of oral adverse effects is maintained when treatment exceeds 12 weeks. A single open-label study that followed a 12-week placebo-controlled trial reported oropharyngeal side effects in 10 of 228 patients treated with ciclesonide (3.5%) ([@b20-ce-1-233]). After 24 weeks of treatment in an open-label study involving 528 patients, oral candidiasis or dysphonia were reported by 5.1% of patients receiving ciclesonide 320 mcg twice daily, significantly less than the 12.8% for fluticasone 330 mcg twice daily (*P*=0.0014) ([@b8-ce-1-233]).

Systemic adverse effects
------------------------

Systemic effects of inhaled corticosteroids occur because a large percentage (80%) of an administered dose of active drug is swallowed ([@b66-ce-1-233]). Additional systemic exposure can occur as the drug is absorbed from the pulmonary fluid into the systemic circulation ([@b35-ce-1-233]). The amount of drug that is available to the systemic circulation, method of delivery, and lipophilicity of the drug influence risk of systemic side effects. The extent of systemic exposure with inhaled corticosteroids is typically reported by the magnitude of HPA axis suppression, serum and urinary cortisol concentrations, and effects on bone growth or mineralization. Systemically active corticosteroids bind to glucocorticoid receptors in the hypothalamus and adrenal pituitary causing a decrease in the amount of corticotropin-releasing hormone and adrenocorticotropic hormone leading to decreased cortisol secretion ([@b44-ce-1-233]).

### HPA axis suppression and cortisol levels

There is clear evidence that ciclesonide does not cause HPA axis suppression after 12 weeks of treatment.

In a 12-week, double-blind, randomized, placebo-controlled study assessing the systemic adverse effect potential of ciclesonide, 164 patients were randomized to receive fluticasone propionate (CFC propellant) 440 mcg daily, ciclesonide 320 mcg once daily, ciclesonide 320 mcg twice daily, or placebo ([@b44-ce-1-233]). Serum and urine cortisol levels were measured at baseline, week 6, and week 12. HPA axis function was preserved with ciclesonide in doses of up to 640 mcg/day. After 12 weeks, changes in mean peak serum cortisol levels and 24-hour urinary free cortisol levels following both doses of ciclesonide were not significantly different from placebo, in contrast to fluticasone propionate 880 mcg/day, which was associated with significant reductions of 9--10% in peak serum cortisol levels and 60% in 24-hour urinary free cortisol levels ([@b44-ce-1-233]). Other studies have also reported a lack of effect of ciclesonide therapy on serum and 24-hour urinary free cortisol corrected for creatinine ([@b61-ce-1-233]; [@b58-ce-1-233]).

In a 12-week study of once-daily inhaled ciclesonide 80 mcg (n=182) or 320 mcg (n=195) compared with inhaled budesonide 200 mcg (n=177) twice daily, no relevant changes in 24-hour urinary cortisol excretion were observed in patients receiving ciclesonide. However, patients who received budesonide had a statistically significant suppression of urine cortisol (*P*\<0.05) ([@b34-ce-1-233]).

Sixty adult patients were randomized in a single-center, double-blind, double-dummy, parallel-group study evaluating HPA axis suppression associated with the use of ciclesonide compared to fluticasone in patients with moderate-to-severe asthma ([@b71-ce-1-233]). Patients received either ciclesonide 320 mcg twice daily, ciclesonide 640 mcg twice daily, fluticasone 440 mcg twice daily, fluticasone 880 mcg twice daily, or placebo for 29 days. Mean serum cortisol AUC~0--24h~ at the end of treatment was significantly suppressed in the high-dose fluticasone group. A cosyntropin stimulation test showed no statistically significant differences among the groups. Twenty-four-hour urinary cortisol levels were significantly increased from baseline at week 4 compared with placebo in the ciclesonide 320 mcg twice-daily group (*P*=0.0224; 95% confidence intervals 0.0023, 0.0283); the other treatment groups did not demonstrate any change in urinary cortisol levels ([@b71-ce-1-233]).

In addition, two abstracts report preliminary information on HPA axis suppression with ciclesonide and an active control in adults ([@b73-ce-1-233]) and in children ([@b60-ce-1-233]). In the study comparing ciclesonide 320 mcg/day with budesonide 400 mcg/day in adults, no relevant change in laboratory parameters or urine cortisol were noted after 12 weeks of treatment ([@b73-ce-1-233]). In the pediatric phase III comparator study, the difference between urinary free cortisol levels in patients treated with ciclesonide 80 mcg twice daily (+1.54 nmol/mmol creatinine) versus patients treated with fluticasone propionate 88 mcg twice daily (−1.83 nmol/mmol creatinine) was statistically significant (*P*=0.0062) ([@b60-ce-1-233]).

The lack of suppressive effect appears to be independent of dose. A study of high-dose ciclesonide 800 mcg/day substantiates the lack of suppressive effect with ciclesonide. The HPA axis function of 12 healthy volunteers was preserved after 800 mcg/day of inhaled doses of ciclesonide (400 mcg twice daily, 800 mcg in the morning, or 800 mcg in the evening) given for 7 days. The effect was independent of time of administration ([@b78-ce-1-233]). There is further evidence for the lack of effect on HPA axis from 26 patients with asthma receiving ciclesonide 320 mcg once daily, or 640 mcg once or twice daily, or fluticasone 440 mcg or 880 mcg twice daily in randomized, double-blind fashion for 9 days ([@b23-ce-1-233]). Although the study was short duration and involved few patients, 24-hour cortisol secretion was unaffected by ciclesonide, even at the high dose.

Furthermore, there is evidence that HPA axis suppression does not appear to develop with longer-term ciclesonide treatment ([@b20-ce-1-233]; [@b57-ce-1-233]). In these placebo-controlled ciclesonide trials, patients received an individualized dose of ciclesonide for 40 weeks following the initial 12-week study. Serum cortisol levels were increased compared with the former steroid treatment (budesonide 800--2000 mcg/day or equivalent) ([@b57-ce-1-233]). There was no evidence that ciclesonide suppressed the HPA axis as evidenced by changes in serum and urine cortisol measurements ([@b20-ce-1-233]). Importantly, these long-term data have been replicated in 661 children aged 5--8.5 years, with ciclesonide 40 or 160 mcg/day associated with minimal changes in urinary-free cortisol levels after 1 year of treatment ([@b11-ce-1-233]).

### Bone mineralization and growth

Orally administered glucocorticoids are known to affect bone mineralization, decrease osteocalcin concentration in healthy volunteers, and decrease bone density in the lumbar spine ([@b36-ce-1-233]; [@b75-ce-1-233]). In young patients, these factors impact bone growth. In adults, these effects can increase the risk of fracture. Glucocorticoids assert their effect on bone predominantly by decreasing bone formation through a negative effect on the function and lifespan of osteoblasts ([@b36-ce-1-233]). Despite the limited systemic absorption of inhaled corticosteroids, the long-term administration of these agents is also believed to impact bone metabolism ([@b66-ce-1-233]; [@b56-ce-1-233]). Laboratory indices of bone formation (bone-specific alkaline phosphatase and serum osteocalcin) have been followed to quantify the impact of therapy.

Over a 52-week study in patients with moderate-to-severe asthma, increased levels of serum bone-specific alkaline phosphatase and serum osteocalcin were observed in patients after receiving ciclesonide compared with the levels obtained while they were on their prestudy doses of steroid (*P*\<0.05), suggesting that the impact of ciclesonide treatment on bone metabolism in these patients was significantly less than the effects of previously used inhaled corticosteroid therapies ([@b57-ce-1-233]).

Studies measuring the effect of lower leg growth in children have been reported. Twenty-four children aged 6--12 years were randomized to receive a daily dose of ciclesonide 40 mcg, 80 mcg, 160 mcg, or placebo over a 12-week period. No statistically significant differences in knemometry results, height measurements, or HPA suppression occurred in any of the patients ([@b5-ce-1-233]). Growth velocity was unaffected by 1 year of treatment with ciclesonide in 661 children aged 5--8.5 years ([@b69-ce-1-233]). During treatment, mean linear growth velocity was 5.73 cm/year with ciclesonide 40 mcg/day, 5.6 cm/year with ciclesonide 160 mcg/day, and 5.75 cm/year with placebo. In the same patient cohort, ciclesonide also had no effect on skeletal maturity, as measured by chronologic to bone age ratio ([@b53-ce-1-233]). A shift from normal to high ratio was seen in 17 patients, although a treatment-related effect seems unlikely since fewer of those taking higher-dose ciclesonide were affected (1.1%), and the incidence with low-dose ciclesonide was similar to that with placebo (4.3 and 4%).

Drug interaction potential
--------------------------

The pharmacokinetic properties of ciclesonide are such that significant drug--drug interactions are not expected with its use. Ciclesonide is activated in airways at the desired site of action and very little of the drug is available to the systemic circulation. A single pharmacokinetic study evaluating ciclesonide and erythromycin coadministration demonstrated a lack of interaction between these medications ([@b50-ce-1-233]). As with other inhaled corticosteroids, drug--drug interactions are not considered to be a clinical concern.

Resource utilization
====================

At present, economic evidence comparing the use of ciclesonide with other inhaled corticosteroids is not available. Ciclesonide, from a clinical standpoint, appears comparable to budesonide and fluticasone propionate, but with less propensity for systemic adverse effects. It is possible that the once-daily administration of ciclesonide coupled with its low adverse event profile will give ciclesonide an advantage over other inhaled corticosteroids. Use of ciclesonide over one of the other inhaled corticosteroids will ultimately depend on additional long-term data as they become available, including its long-term adverse effect profile and impact on HRQOL. Economic data, including the effect of ciclesonide treatment on both direct and indirect medical costs, will need to be factored into the decision-making process to determine its place in therapy with regard to the other inhaled corticosteroids.

In general, inhaled corticosteroids are considered the most effective therapy for reducing asthma exacerbations and studies have reported that the use of these agents reduce medical costs and decrease the use of healthcare resources ([@b33-ce-1-233]). A recent meta analysis examined the long-term effects of inhaled corticosteroids, long-acting beta~2~ agonists, leukotriene pathway modifiers/receptor antagonists, and antiimmunoglobulin E antibody therapies. Of these agents, inhaled corticosteroids were found to have the greatest impact on the reduction of asthma exacerbations (55% vs placebo; relative risk 0.46, 95% confidence intervals 0.34, 0.62; *P*\<0.001) ([@b68-ce-1-233]). These reductions in exacerbations translate to economic savings from decreased hospitalizations, decreased emergency room visits, and a decrease in physician visits and use of rescue medications. In order for an inhaled corticosteroid to produce its positive effects, it must be used continuously to keep the inflammatory process in check.

Patient group/population
========================

Asthma affects all age groups, from pediatric patients to the elderly. Available evidence for ciclesonide demonstrates efficacy in patients with persistent asthma that is similar to other currently available inhaled corticosteroids. Inhaled corticosteroids are the mainstay of treatment for patients with persistent asthma. Any patient with symptom frequency that suggests persistent disease would benefit from maintenance treatment with an agent such as ciclesonide. The evidence for a lack of effect on growth rate and skeletal maturation in children in the long term (1 year) indicates that ciclesonide is suitable for pediatric use.

Dosage, administration, and formulations
========================================

Ciclesonide (Alvesco^®^) is available in a 80 mcg and 160 mcg metered-dose inhaler, with hydrofluoroalkane propellant. Approved dosages and indications vary between different countries, and readers are advised to consult their local prescribing information (Anon. 2006). The recommended starting dose is usually 160 mcg once daily, preferably in the evening. Maintenance on 80 mcg once daily may be effective in some patients. No dosage adjustment is necessary in the elderly or in patients with hepatic or renal impairment.

Place in therapy
================

The unique pharmacokinetic profile of ciclesonide confers a potential advantage in that there is minimal systemic absorption of active drug, which appears to be sustained as shown by a lack of HPA axis suppression after 1 year of treatment. Further evidence will confirm if efficacy is sustained in the longer term with approved doses, and if the decrease in systemic exposure is linked to an overall increased safety profile. The decrease in adverse effects that have been observed in short-term trials may be beneficial in some patients for whom the local effects are bothersome and may lead to disruptions in therapy. In addition, patients with more severe disease who are being treated with higher doses of inhaled corticosteroids may also benefit because of the apparent decrease in systemic exposure associated with ciclesonide use. The drug appears to have a role in the management of pediatric patients with asthma, and is not associated with growth retardation in long-term use.

The available evidence indicates that ciclesonide is as effective as fluticasone and budesonide for the management of persistent asthma, as shown by improvements in lung function parameters, symptom scores, and use of rescue medications. Inhaled corticosteroids are considered to be the foundation of asthma management in patients with persistent disease ([Table 2](#t2-ce-1-233){ref-type="table"}). It is expected that ciclesonide will be included in updated guidelines as a primary therapy along with other inhaled corticosteroids. Currently, the use of combination inhalers (beta-agonist/corticosteroid) is recommended as a means to streamline therapy in patients with persistent asthma. ([@b3-ce-1-233]; [@b16-ce-1-233]). Ciclesonide is not available in a combination formulation and therefore patients would be required to have two separate inhalers. There is evidence that lung function improvements are maintained for up to 1 year of treatment.

The impact of ciclesonide use on overall disease course, DALYs, and hospitalization rate as compared with other currently available inhaled corticosteroids has not been reported. These measures are important to the overall evaluation of the expected role of ciclesonide in the management of persistent asthma.

###### 

Evidence base included in the review

  **Category**                                                            **Number of records**   
  ----------------------------------------------------------------------- ----------------------- --------------------------------------------
  Initial search                                                          20                      61
    records excluded                                                      12                      42
    records included                                                      8                       19
  Additional studies identified[a](#tfn1-ce-1-233){ref-type="table-fn"}   3                       3
  Search update, new records                                              22                      22
    records excluded                                                      12                      18
    records included                                                      10                      4
  Level 1 clinical evidence                                               2                       0
  Level 2 clinical evidence                                               18                      27[b](#tfn2-ce-1-233){ref-type="table-fn"}
  Level ≥3 clinical evidence                                              1                       0
    trials other than RCT                                                 1                       
    case reports                                                                                  
  Economic evidence                                                       0                       0
  Total records included                                                  21                      27

Additional studies identified = any relevant study that was picked up from a source other than the main searches, e.g. a reference list.

Includes several subanalyses from six RCTs.

For definitions of levels of evidence see Editorial Information on inside back cover.

RCT, randomized controlled trial.

###### 

Pharmacologic management of asthma: stepped approach (adapted from Anon. 2005b)

  **Category of asthma**                                      **Characteristics**                                                                                                                                                                                      **Daily medication[a](#tfn5-ce-1-233){ref-type="table-fn"}**
  ----------------------------------------------------------- -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  **Adults and children \>5 years**                                                                                                                                                                                                                                    
  Intermittent                                                Symptoms \<once/weekBrief exacerbationsNocturnal symptoms ≤2 nights/monthFEV~1~ or PEF ≥80% predictedPEF or FEV~1~ variability \<20%                                                                     None
  Mild persistent                                             Symptoms \>once/week, but \<once/dayExacerbations may affect activity and sleepNocturnal symptoms \>2 nights/monthFEV~1~ or PEF ≥80% predictedPEF or FEV~1~ variability 20--30%                          Low-dose inhaled corticosteroidAlternative: cromolyn, leukotriene modifier, nedocromil, or sustained-release theophylline
  Moderate persistent                                         Daily symptomsExacerbations may affect activity and sleepNocturnal symptoms \>once/weekDaily use of short-acting inhaled beta~2~ agonistFEV~1~ or PEF 60--80% predictedPEF or FEV~1~ variability \>30%   Low to medium-dose inhaled corticosteroid and long-acting inhaled beta~2~ agonistAlternative: -- Increase inhaled corticosteroid within medium dose range or-- Low to medium-dose inhaled corticosteroid and either leukotriene modifier or theophylline
  Severe persistent                                           Continuous symptomsFrequent exacerbationsFrequent nocturnal symptomsLimitation of physical activitiesFEV~1~ or PEF 60% predictedPEF or FEV~1~ variability \>30%                                          High-dose inhaled corticosteroid and long-acting inhaled beta~2~ agonistIf needed: oral corticosteroid, sustained-release theophylline, leukotriene modifier, antiimmunoglobulin E antibody (adults and children ≥2 years)
  **Infants and young children \<5 years**                                                                                                                                                                                                                             
  Mild intermittent[b](#tfn6-ce-1-233){ref-type="table-fn"}   Symptoms \<once/weekBrief exacerbationsNocturnal symptoms \<2 nights/monthFEV~1~ or PEF ≥80% predictedPEF or FEV~1~ variability \<20%                                                                    None
  Mild persistent                                             Symptoms \>once/week, but \<once/dayExacerbations may affect activityNocturnal symptoms \>2 nights/monthFEV~1~ or PEF ≥80% predictedPEF or FEV~1~ variability 20--30%                                    Low-dose inhaled corticosteroidAlternative: cromolyn, leukotriene modifier, nedocromil, or sustained-release theophylline
  Moderate persistent                                         Daily symptomsExacerbations affect activityNocturnal symptoms \>once/weekFEV~1~ or PEF 60--80% predictedPEF or FEV~1~ variability \>30%                                                                  Low-dose inhaled corticosteroid and long-acting inhaled beta~2~ agonist (if needed medium dose can be used) orMedium-dose inhaled corticosteroidAlternative: low-dose inhaled corticosteroid (if needed medium dose can be used) and leukotriene modifier or theophylline
  Severe persistent                                           Continuous symptomsFrequent nocturnal symptomsLimitation of physical activityFEV~1~ or PEF ≤60% predictedPEF or FEV~1~ variability \>30%                                                                 High-dose inhaled corticosteroid and long-acting inhaled beta~2~ agonistIf needed: oral corticosteroid

A short-acting inhaled beta~2~ agonist should be used as needed to relieve acute symptoms; use should be limited to no more than 3--4 times/day.

Children with intermittent asthma but severe exacerbations should be managed as having moderate persistent asthma.

FEV~1~, forced expiratory volume in 1 s; PEF, peak expiratory flow.

###### 

Pharmacokinetic profiles of currently available inhaled corticosteroids ([@b63-ce-1-233]; [@b2-ce-1-233]; [@b35-ce-1-233]; [@b80-ce-1-233])

  **Drug**                    **Lung deposition (MDI-HFA) (%)**            **Oral bioavailability[a](#tfn8-ce-1-233){ref-type="table-fn"} (%)**   **Protein binding (%)**   **Metabolism**               **Excretion**              **Suggested dosing frequency**
  --------------------------- -------------------------------------------- ---------------------------------------------------------------------- ------------------------- ---------------------------- -------------------------- -------------------------------------------------------------
  Beclomethasone propionate   51[b](#tfn9-ce-1-233){ref-type="table-fn"}   26                                                                     87                        Hepatic                      Feces, urine (\<10%)       Twice daily
  Budesonide                  28                                           11--32                                                                 88                        Hepatic                      Urine (60%), feces         Once or twice daily[a](#tfn8-ce-1-233){ref-type="table-fn"}
  Ciclesonide                 52                                           \<1                                                                    99                        Hepatic                      Feces (77.9%)              Once daily
  Flunisolide                 39                                           7                                                                      80                        Hepatic                      Renal (50%), feces (40%)   Twice daily
  Fluticasone propionate      16                                           \<1                                                                    90                        Hepatic                      Feces (urine \<0.02%)      Twice daily
  Mometasone furoate          --                                           11                                                                     98--99                    Hepatic                      Feces (74%), urine (8%)    Once or twice daily
  Triamcinolone acetonide     22[b](#tfn9-ce-1-233){ref-type="table-fn"}   21.5                                                                   71                        Mostly hepatic, some renal   Urine (40%), feces (60%)   Twice daily

Depends on the delivery device used.

Delivery device not specified.

MDI-HFA, metered-dose inhaler with hydrofluoroalkane propellant.

###### 

Advantages and disadvantages of portable delivery devices for inhaled corticosteroids ([@b24-ce-1-233])

  ----------------------------------------------------------------------------------------------------------------------------------------------------
  **Device**                         **Advantages**                                         **Disadvantages**
  ---------------------------------- ------------------------------------------------------ ----------------------------------------------------------
  Pressurized metered-dose inhaler   No contamination\                                      Requires coordination and good technique\
                                     Dose--dose reproducibility\                            High pharyngeal deposition\
                                     Some can be used with breath-actuated mouthpiece       Difficult to determine remaining dosage

  Holding chamber, spacers           Decreased need for patient coordination\               Added expense\
                                     Decreased pharyngeal deposition                        Less portable than metered-dose inhaler alone\
                                                                                            Dose delivered might be reduced

  Dry-powder inhalers                Less patient coordination required: breath actuated\   Can deliver high pharyngeal deposition\
                                     No propellant required\                                Moderate to high inspiratory flow required for actuation
                                     Dose counters in most newer dosage forms               
  ----------------------------------------------------------------------------------------------------------------------------------------------------

###### 

Effect of ciclesonide on lung function in patients with moderate to severe asthma (level 2 evidence; all trials randomized, double-blind, parallel-group, placebo-controlled, 12 weeks' duration)

  **Treatment (mcg)**                                    **n**   **Baseline FEV~1~ (% of predicted)**   **Outcome**                                                           **Reference**                                                                                                                                                                                                                
  ------------------------------------------------------ ------- -------------------------------------- --------------------------------------------------------------------- --------------- ---------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------- -----------------
  CIC 160 qd                                             107     60--90                                 Maintained with both doses[a](#tfn12-ce-1-233){ref-type="table-fn"}   NR              +59                                                                                                  Stable for both doses (*P*\<0.0001)                                                                     [@b21-ce-1-233]
  CIC 640 qd                                             112                                                                                                                  +9                                                                                                                                                                                                                           
  Placebo                                                110                                            −144                                                                                  −161                                                                                                 −29                                                                                                     
  CIC 80 qd                                              120     60--95                                 +130 (*P*=0.0044)[b](#tfn13-ce-1-233){ref-type="table-fn"}            NR              [+](#tfn17-ce-1-233){ref-type="table-fn"}190 (*P*=0.0203)[b](#tfn13-ce-1-233){ref-type="table-fn"}   +2[c](#tfn14-ce-1-233){ref-type="table-fn"} (*P*=0.0012)[b](#tfn13-ce-1-233){ref-type="table-fn"}       [@b41-ce-1-233]
  CIC 320 qd                                             115                                            +190 (*P*=0.0001)[b](#tfn13-ce-1-233){ref-type="table-fn"}                            +200 (*P*=0.0197)[b](#tfn13-ce-1-233){ref-type="table-fn"}                                           +3[c](#tfn14-ce-1-233){ref-type="table-fn"} (*P*=0.0006)[b](#tfn13-ce-1-233){ref-type="table-fn"}       
  Placebo                                                125                                            −30                                                                                   +40                                                                                                  −18                                                                                                     
  CIC 80 qd                                              257     60--85                                 +280 (*P*≤0.0007)[b](#tfn13-ce-1-233){ref-type="table-fn"}            NR              NR                                                                                                   10.93[c](#tfn14-ce-1-233){ref-type="table-fn"} (*P*=0.0003)[b](#tfn13-ce-1-233){ref-type="table-fn"}    [@b58-ce-1-233]
  CIC 160 qd                                             250                                            +290 (*P*≤0.0007)[b](#tfn13-ce-1-233){ref-type="table-fn"}                                                                                                                                 21.06[c](#tfn14-ce-1-233){ref-type="table-fn"} (*P*\<0.0001)[b](#tfn13-ce-1-233){ref-type="table-fn"}   
  CIC 320 qd                                             255                                            +310 (*P*≤0.0007)[b](#tfn13-ce-1-233){ref-type="table-fn"}                                                                                                                                 17.22[c](#tfn14-ce-1-233){ref-type="table-fn"} (*P*\<0.0001)[b](#tfn13-ce-1-233){ref-type="table-fn"}   
  Placebo                                                249                                            +170                                                                                                                                                                                       −1.70[c](#tfn14-ce-1-233){ref-type="table-fn"}                                                          
  CIC 320 bid[d](#tfn15-ce-1-233){ref-type="table-fn"}   47      40--80                                 Trend toward higher values[e](#tfn16-ce-1-233){ref-type="table-fn"}   NR              NR                                                                                                   +4.32[b](#tfn13-ce-1-233){ref-type="table-fn"},[c](#tfn14-ce-1-233){ref-type="table-fn"}                [@b7-ce-1-233]
  CIC 640 bid[d](#tfn15-ce-1-233){ref-type="table-fn"}   49                                             NR                                                                    NR              +15.97[b](#tfn13-ce-1-233){ref-type="table-fn"},[c](#tfn14-ce-1-233){ref-type="table-fn"}                                                                                                                    
  Placebo[d](#tfn15-ce-1-233){ref-type="table-fn"}       45                                             NR                                                                    NR              NR                                                                                                   −0.7[b](#tfn13-ce-1-233){ref-type="table-fn"},[c](#tfn14-ce-1-233){ref-type="table-fn"}                 

All *P* values vs placebo.

*P*=0.007 for CIC 160 and *P*=0.0108 for CIC 640.

Reported as a mean value.

PEF change from baseline to week 12.

Patients also received oral prednisone 5--30 mg/day and/or 10--60 mg on alternate days.

*P*=0.0237 CIC 320 bid vs placebo, *P*=0.0277 CIC 640 bid vs placebo.

+, increase over study period; −, decrease over study period; bid, twice daily; CIC, ciclesonide; FEV~1~, forced expiratory volume in 1 s; FVC, forced vital capacity; NR, not reported; NS, not significant; PEF, peak expiratory flow; qd, once daily.

###### 

Effect on lung function of ciclesonide compared with active treatment in patients aged \>12 years with moderate to severe asthma (level 2 evidence; all trials double-blind unless stated)

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  **Treatment (mcg) \[duration\]**                       **n**                                                                                    **Baseline FEV~1~ (% of predicted)**           **Outcome**                                                 **Reference**                                                                                                                                                                                                                                         
  ------------------------------------------------------ ---------------------------------------------------------------------------------------- ---------------------------------------------- ----------------------------------------------------------- -------------------------------------------------- ------------------------------------------------------------------ ------------------------------------------------------------------ ------------------------------------------------------------ -----------------
  CIC 320 qd\                                            399[a](#tfn18-ce-1-233){ref-type="table-fn"}                                             50--90                                         +411[c](#tfn20-ce-1-233){ref-type="table-fn"}\              NR                                                 Increase in both groups (no values given); CIC\>BUD (*P*=0.0359)   NR                                                                 NR                                                           [@b12-ce-1-233]
  BUD 400 qd\                                                                                                                                                                                    +319[c](#tfn20-ce-1-233){ref-type="table-fn"}\                                                                                                                                                                                                                                                                    
  \[12 w\]                                                                                                                                                                                       CIC\>BUD (*P*=0.0374)                                                                                                                                                                                                                                                                                             

  CIC 160 qd\                                            266\                                                                                     80--100                                        +489[c](#tfn20-ce-1-233){ref-type="table-fn"}\              +20.45\                                            +530[c](#tfn20-ce-1-233){ref-type="table-fn"}\                     +33[c](#tfn20-ce-1-233){ref-type="table-fn"}\                      NR                                                           [@b18-ce-1-233]
  FP 88 bid\                                             263                                                                                                                                     +499[c](#tfn20-ce-1-233){ref-type="table-fn"}               +20.4                                              +499[c](#tfn20-ce-1-233){ref-type="table-fn"}                      +36[c](#tfn20-ce-1-233){ref-type="table-fn"}                                                                                    
  \[12 w\]                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         

  CIC 160 qd A\                                          139\                                                                                     ≥70                                            −36[d](#tfn21-ce-1-233){ref-type="table-fn"} (*P*=0.383)\   NR                                                 +5[d](#tfn21-ce-1-233){ref-type="table-fn"} (*P*=0.905)\           −4.4[d](#tfn21-ce-1-233){ref-type="table-fn"} (*P*=0.464)\         −1.1[d](#tfn21-ce-1-233){ref-type="table-fn"} (*P*=0.855)\   [@b55-ce-1-233]
  CIC 160 qd P\                                          131\                                                                                                                                    +22[d](#tfn21-ce-1-233){ref-type="table-fn"} (*P*=0.598)\                                                      +2[d](#tfn21-ce-1-233){ref-type="table-fn"} (*P*=0.970)\           +9.3[d](#tfn21-ce-1-233){ref-type="table-fn"} (*P*=0.131)\         +4.0[d](#tfn21-ce-1-233){ref-type="table-fn"} (*P*=0.490)\   
  BUD 200 bid\                                           133                                                                                                                                     0                                                                                                              0                                                                  0                                                                  0                                                            
  \[12 w\]                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         

  CIC 160 bid\                                           531[a](#tfn18-ce-1-233){ref-type="table-fn"}                                             54                                             NR                                                          +21.24[c](#tfn20-ce-1-233){ref-type="table-fn"}\   NR                                                                 18.11[c](#tfn20-ce-1-233){ref-type="table-fn"}\                    NR                                                           [@b79-ce-1-233]
  CIC 320 bid\                                                                                                                                                                                                                                               +24.46[c](#tfn20-ce-1-233){ref-type="table-fn"}\                                                                      20.71[c](#tfn20-ce-1-233){ref-type="table-fn"}\                                                                                 
  FP 440 bid[b](#tfn19-ce-1-233){ref-type="table-fn"}\                                                                                                                                                                                                       +30.09[c](#tfn20-ce-1-233){ref-type="table-fn"}                                                                       31.73[c](#tfn20-ce-1-233){ref-type="table-fn"}\                                                                                 
  Placebo\                                                                                                                                                                                                                                                                                                                                                                         −9.69[c](#tfn20-ce-1-233){ref-type="table-fn"}                                                                                  
  \[12 w\]                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         

  CIC 320 qd\                                            319[a](#tfn18-ce-1-233){ref-type="table-fn"},[e](#tfn22-ce-1-233){ref-type="table-fn"}   NR                                             NR                                                          NR                                                 NR                                                                 +16[c](#tfn20-ce-1-233){ref-type="table-fn"}\                      NR                                                           [@b1-ce-1-233]
  CIC 320 bid\                                                                                                                                                                                                                                                                                                                                                                     +24[c](#tfn20-ce-1-233){ref-type="table-fn"} (*P*=0.001 vs BUD)\                                                                
  BUD 400 bid\                                                                                                                                                                                                                                                                                                                                                                     +6[c](#tfn20-ce-1-233){ref-type="table-fn"}                                                                                     
  \[8 w\]                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          

  CIC 320 bid\                                           528[a](#tfn18-ce-1-233){ref-type="table-fn"},[e](#tfn22-ce-1-233){ref-type="table-fn"}   ≥80                                            +11\                                                        NR                                                 NR                                                                 +36[c](#tfn20-ce-1-233){ref-type="table-fn"}\                      Similar to morning PEF (data shown graphically)              [@b8-ce-1-233]
  FP 330 bid\                                                                                                                                                                                    [+](#tfn23-ce-1-233){ref-type="table-fn"}38                                                                                                                                       +22[c](#tfn20-ce-1-233){ref-type="table-fn"}                                                                                    
  \[24 w\]                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         

  CIC 320 qd\                                            179\                                                                                     65--95                                         −170\                                                       −6\                                                −120 (*P*=0.01 vs BUD)\                                            −3[c](#tfn20-ce-1-233){ref-type="table-fn"}\                       −2[c](#tfn20-ce-1-233){ref-type="table-fn"}\                 [@b13-ce-1-233]
  BUD 320 qd\                                            180                                                                                                                                     −220                                                        −8                                                 −210                                                               −10[c](#tfn20-ce-1-233){ref-type="table-fn"}                       −4[c](#tfn20-ce-1-233){ref-type="table-fn"}                  
  \[12 w\]                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         

  CIC 320 qd\                                            472[a](#tfn18-ce-1-233){ref-type="table-fn"},[e](#tfn22-ce-1-233){ref-type="table-fn"}   60--80                                         +171\                                                       NR                                                 NR                                                                 NR                                                                 NR                                                           [@b14-ce-1-233]
  FP 200 bid\                                                                                                                                                                                    +186                                                                                                                                                                                                                                                                                                              
  \[12 w\]                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         

  CIC 80 qd\                                             182\                                                                                     73[c](#tfn20-ce-1-233){ref-type="table-fn"}\   +267[c](#tfn20-ce-1-233){ref-type="table-fn"}\              +10.8\                                             NR                                                                 +12[c](#tfn20-ce-1-233){ref-type="table-fn"}\                      NR                                                           [@b34-ce-1-233]
  CIC 320 qd\                                            195\                                                                                     72[c](#tfn20-ce-1-233){ref-type="table-fn"}\   +256[c](#tfn20-ce-1-233){ref-type="table-fn"}\              +10.4\                                                                                                                +17[c](#tfn20-ce-1-233){ref-type="table-fn"}\                                                                                   
  BUD 200 bid\                                           177                                                                                      72[c](#tfn20-ce-1-233){ref-type="table-fn"}    +355[c](#tfn20-ce-1-233){ref-type="table-fn"}               +14.4                                                                                                                 +21[c](#tfn20-ce-1-233){ref-type="table-fn"}                                                                                    
  \[12 w\]                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         

  CIC 640 bid\                                           130[a](#tfn18-ce-1-233){ref-type="table-fn"}                                             NR                                             +429\                                                       NR                                                 NR                                                                 +52[c](#tfn20-ce-1-233){ref-type="table-fn"}\                      NR                                                           [@b62-ce-1-233]
  PRED 40 mg qd\                                                                                                                                                                                 +428                                                                                                                                                                              +53[c](#tfn20-ce-1-233){ref-type="table-fn"}                                                                                    
  \[2 w\]                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Numbers of patients in each group not specified.

FP dose 37% higher to maintain blinding.

Reported as a mean value.

Least squares mean vs budesonide; intent-to-treat analysis.

Open-label design.

+, increase; −, decrease; A, [am]{.smallcaps}; bid, twice daily; BUD, budesonide; CIC, ciclesonide; FEV~1~, forced expiratory volume in 1 s; FVC, forced vital capacity; FP, fluticasone propionate; NR, not reported; P, PM; PRED, prednisolone; PEF, peak expiratory flow; qd, once daily; w, week.

###### 

Effect on symptoms and use of rescue medications of ciclesonide compared with placebo and active treatment in patients with asthma (level 2 evidence; all trials in adults, randomized)

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  **Treatment (mcg) \[duration\]**   **n**   **Baseline FEV~1~ (% of predicted)**   **Outcome**                                                                             **Reference**                                                  
  ---------------------------------- ------- -------------------------------------- --------------------------------------------------------------------------------------- -------------------------------------------------------------- --------------------------------------------------
  **Placebo-controlled trials**                                                                                                                                                                                                            

  CIC 80 qd\                         360     60--90                                 Median number of symptom-free days was higher in patients treated with CIC vs placebo   0[a](#tfn24-ce-1-233){ref-type="table-fn"}\                    [@b41-ce-1-233]
  CIC 320 qd\                                                                                                                                                               0[a](#tfn24-ce-1-233){ref-type="table-fn"}\                    
  Placebo\                                                                                                                                                                  +0.5[a](#tfn24-ce-1-233){ref-type="table-fn"}                  
  \[12 w\]                                                                                                                                                                                                                                 

  CIC 80 qd\                         257\    60--85                                 NR                                                                                      −0.86[a](#tfn24-ce-1-233){ref-type="table-fn"} (*P*≤0.001)\    [@b58-ce-1-233]
  CIC 160 qd\                        250\                                                                                                                                   −1.02[a](#tfn24-ce-1-233){ref-type="table-fn"} (*P*≤0.001)\    
  CIC 320 qd\                        255\                                                                                                                                   −1.04[a](#tfn24-ce-1-233){ref-type="table-fn"} (*P*≤0.001)\    
  Placebo\                           249                                                                                                                                    +0.42[a](#tfn24-ce-1-233){ref-type="table-fn"}                 
  \[12 w\]                                                                                                                                                                                                                                 

  CIC 320 bid\                       47\     40--80                                 NR                                                                                      −0.07[a](#tfn24-ce-1-233){ref-type="table-fn"}\                [@b7-ce-1-233]
  CIC 640 bid\                       49\                                                                                                                                    −0.08[a](#tfn24-ce-1-233){ref-type="table-fn"}\                
  Placebo\                           45                                                                                                                                     +0.32[a](#tfn24-ce-1-233){ref-type="table-fn"}                 
  \[12 w\]                                                                                                                                                                                                                                 

  **Comparator trials**                                                                                                                                                                                                                    

  CIC 320 qd\                        399     NR                                     Similar between groups                                                                  Similar between groups                                         [@b12-ce-1-233]
  BUD 400 qd\                                                                                                                                                                                                                              
  \[12 w\]                                                                                                                                                                                                                                 

  CIC 160 qd\                        266\    80--100                                79\                                                                                     −1.00[a](#tfn24-ce-1-233){ref-type="table-fn"}\                [@b17-ce-1-233], [@b18-ce-1-233],[@b19-ce-1-233]
  FP 88 bid\                         263                                            77                                                                                      −1.21[a](#tfn24-ce-1-233){ref-type="table-fn"}                 
  \[12 w\]                                                                                                                                                                                                                                 

  CIC 160 qd A\                      139\    ≥70                                    89\                                                                                     Similar between groups                                         [@b55-ce-1-233]
  CIC 160 qd P\                      131\                                           91\                                                                                                                                                    
  BUD 200 bid\                       133                                            93                                                                                                                                                     
  \[12 w\]                                                                                                                                                                                                                                 

  CIC 320 qd\                        319     NR                                     NR                                                                                      NR\                                                            [@b1-ce-1-233]
  CIC 320 bid\                                                                                                                                                              −0.44[c](#tfn26-ce-1-233){ref-type="table-fn"}\                
  BUD 400 bid\                                                                                                                                                              NR                                                             
  \[8 w\]                                                                                                                                                                                                                                  

  CIC 320 bid\                       528     ≥80                                    Similar between groups                                                                  Similar between groups                                         [@b8-ce-1-233]
  FP 330 bid\                                                                                                                                                                                                                              
  \[24 w\]                                                                                                                                                                                                                                 

  CIC 320 qd\                        179\    65--95                                 43.6[d](#tfn27-ce-1-233){ref-type="table-fn"}\                                          57.5[b](#tfn25-ce-1-233){ref-type="table-fn"}\                 [@b13-ce-1-233]
  BUD 320 qd\                        180                                            25.8                                                                                    53.6[b](#tfn25-ce-1-233){ref-type="table-fn"}                  
  \[12 w\]                                                                                                                                                                                                                                 

  CIC 320 qd\                        472     60--80                                 88\                                                                                     89[b](#tfn25-ce-1-233){ref-type="table-fn"}\                   [@b14-ce-1-233]
  FP 200 bid\                                                                       88                                                                                      88[b](#tfn25-ce-1-233){ref-type="table-fn"}                    
  \[12 w\]                                                                                                                                                                                                                                 

  CIC 80 qd\                         182\    73\                                    Approx. 40% for all treatment groups                                                    −0.68[a](#tfn24-ce-1-233){ref-type="table-fn"} (*P*\<0.001)\   [@b34-ce-1-233]
  CIC 320 qd\                        195\    72\                                                                                                                            −1.00[a](#tfn24-ce-1-233){ref-type="table-fn"} (*P*\<0.001)\   
  BUD 200 bid\                       177     72                                                                                                                             −1.04[a](#tfn24-ce-1-233){ref-type="table-fn"} (*P*\<0.001)    
  \[12 w\]                                                                                                                                                                                                                                 

  CIC 640 bid\                       130     NR                                     Similar between groups                                                                  Similar between groups                                         [@b62-ce-1-233]
  PRED 40 mg qd\                                                                                                                                                                                                                           
  \[2 w\]                                                                                                                                                                                                                                  
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Change from baseline.

Percentage of days without use.

*P*=0.029 vs CIC 320qd, *P*=0.007 vs BUD.

*P*=0.017.

+, increase; −, decrease; bid, twice daily; A, [am]{.smallcaps}; BUD, budesonide; CIC, ciclesonide; FEV~1~, forced expiratory volume in 1 s; FP, fluticasone propionate; NR, not reported; P, PM; qd, once daily.

###### 

Effect on quality of life of ciclesonide compared with placebo or active treatment (level 2 evidence; all studies randomized, multicenter, double-blind, parallel-group, placebo-controlled, 12 weeks' duration)

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  **Treatment (mcg)**                                     **n**   **Baseline FEV~1~ (% of predicted)**   **Outcome: patients achieving an MID (≥0.5) in QOL score (%)**   **Reference**
  ------------------------------------------------------- ------- -------------------------------------- ---------------------------------------------------------------- ----------------------------------
  **Studies in adults and adolescents aged \>12 years**                                                                                                                   

  CIC 160 bid\                                            531     40--65                                 42.5\                                                            [@b10-ce-1-233]
  CIC 320 bid\                                                                                           43\                                                              
  FP 440 bid[a](#tfn29-ce-1-233){ref-type="table-fn"}\                                                   58.8\                                                            
  Placebo                                                                                                26.8                                                             

  CIC 80 qd\                                              1015    60--85                                 47\                                                              [@b52-ce-1-233]
  CIC 160 qd\                                                                                            50\                                                              
  CIC 320 qd\                                                                                            50.6\                                                            
  Placebo                                                                                                31                                                               

  **Study in pediatric patients aged 7--17 years**                                                                                                                        

  CIC 40 qd\                                              793     60--85                                 46.1\                                                            [@b47-ce-1-233]; [@b29-ce-1-233]
  CIC 80 qd\                                                                                             50\                                                              
  CIC 160 qd\                                                                                            52.5\                                                            
  Placebo                                                                                                36.5                                                             

  CIC 160 qd\                                             340\    NR                                     53.8\                                                            [@b76-ce-1-233]
  BUD 400 qd                                              173                                            50.6                                                             
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

FP dose 37% higher to maintain blinding.

bid, twice daily; BUD, budesonide; CIC, ciclesonide; FEV~1~, forced expiratory volume in 1 s; FP, fluticasone propionate; MID, minimally important difference; qd, once daily.

###### 

Incidence of oropharyngeal adverse events with ciclesonide compared with placebo or active treatment[a](#tfn31-ce-1-233){ref-type="table-fn"} (adapted from [@b27-ce-1-233])

  **Adverse event**   **Incidence of event/patient year**          
  ------------------- ------------------------------------- ------ ------
  Candidiasis         0.02                                  0.02   0.07
  Hoarseness          0.03                                  0.03   0.07

Cough not reported.

Beclomethasone, budesonide, or fluticasone.
